Servier Canada Announces the Availability of ZEVALIN®, the Only Single-course Chemo-free Treatment Regimen for the Treatment of Relapsed or Refractory Indolent B-cell Non-Hodgkin’s Lymphoma.

Servier Canada announces the Expansion of its Oncology Portfolio through the acquisition by Servier group of Shire’s oncology branch

Servier Canada, in collaboration with Hypertension Canada, launches the GETDOWNBP Hypertension Management mobile App

Servier Canada and the New Brunswick Health Research Foundation announce the creation of the Servier-New Brunswick Cardiac Health Improvement Fund (CHIF)